Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 25;8(3):234-243.
doi: 10.31547/bct-2025-002. eCollection 2025 Aug 25.

Role of Composite Measurable Residual Disease Assessment with PET-CT and flow cytometry in Multiple Myeloma patients undergoing Autologous Transplant

Affiliations

Role of Composite Measurable Residual Disease Assessment with PET-CT and flow cytometry in Multiple Myeloma patients undergoing Autologous Transplant

Rudra Narayan Swain et al. Blood Cell Ther. .

Abstract

Background: Bone marrow (BM) Measurable Residual Disease (MRD) assessments underestimate disease burden in multiple myeloma, as focal lesions can exist outside the marrow. Functional imaging, like positron emission tomography-computed tomography (PET-CT), offers valuable insights into residual disease beyond the marrow. Combining marrow flow cytometry (FCM) with PET-CT for a composite MRD (cMRD) assessment before and after autologous stem cell transplant (ASCT) is expected to provide prognostic information, particularly in settings where patients receive extended duration of anti-myeloma therapy prior to ASCT.

Methods: In this retrospective cohort study, we evaluated the prognostic impact of cMRD in newly diagnosed multiple myeloma (NDMM) patients who underwent triplet/quadruplet-based induction followed by ASCT from January 2017 to June 2023. cMRD was assessed before ASCT and again around day 100 post-transplant. cMRD negativity was defined as undetectable residual clonal plasma cells (sensitivity 1×10-5) on multi coloured FCM and PET-CT negativity per The International Myeloma Working Group criteria.

Results: Among 106 patients undergoing ASCT, 82 had cMRD assessments before and on day 100 post-ASCT. Median pre-ASCT treatment duration was 11 months (interquartile range [IQR]: 4-18). At the pre-ASCT time point, sixty seven percent patients were bone marrow MRD negative (BM-MRDPRE-), while 38% were PET-CT negative (PETPRE-). Post-ASCT, these rates were 74% (BM-MRDPOST-) and 49% (PET-CTPOST-) respectively. At a median follow-up of 35 months (IQR: 23.5-58), median time to next treatment (TTNT) and overall survival (OS) were not reached. At three years, TTNT was significantly higher in patients who were cMRD-negative before ASCT compared to those who were cMRD-positive [91% (confidence interval (CI): 77-100) versus 67% (CI: 52-80); p=0.027]. BM-MRDPRE- and PETPRE- were both independently associated with improved TTNT on univariate analysis [Hazard Ratio: 0.32 (0.14-0.74) and 0.45 (0.23-0.94) respectively]. Post-ASCT cMRD status did not significantly impact TTNT [82% (CI: 68-96) versus 65% (CI: 51-69); p=0.116]. Three-year TTNT rates were similar among patients with and without baseline high-risk cytogenetic abnormalities (HRCA) if they maintained sequential cMRD negativity. In multivariate analysis, the absence of HRCA, complete response before ASCT, cMRDPRE-, and sustained cMRD negativity at both time points were independent predictors of longer TTNT.

Conclusions: Pre-ASCT cMRD assessment using both PET-CT and bone marrow FCM provides prognostic value in NDMM. This approach is particularly relevant in real-world settings where patients often receive prolonged induction therapy before ASCT.

Keywords: PET-CT; autologous transplant; measurable residual disease; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website. DL is one of the editors of Blood Cell Therapy. He was not involved in the editorial evaluation or decision to accept this article for publication.

Figures

Figure 1.
Figure 1.
MRD Conversion Pre and Post-Autologous Stem Cell Transplant using both modalities (BM-MRD and PET-CT) Numbers in solid black indicate the response status before and after ASCT. Numbers in solid white indicate proportion of patients transitioning from one MRD category to another after ASCT. Pos, positive; Neg, negative; BM-MRD, bone marrow measurable residual disease; cMRD, composite measurable residual disease using BM-MRD and PET-CT)
Figure 2.
Figure 2.
Kaplan Meier survival analysis showing TTNT plots between (A) cMRDpre Positive vs Negative, (B) cMRDpost Positive vs Negative, (C) cMRDpre stratified by status of Both modalities (BM MRD and PET CT), and (D) cMRDpost stratified by status of both modalities (BM MRD and PET CT)
Figure 3.
Figure 3.
Kaplan Meier survival analysis showing TTNT plots stratified by groups based on Pre-ASCT and Post-ASCT cMRD status
Figure 4.
Figure 4.
Multivariate analysis for (A) TTNT among patients who had sequential cMRD assessment at two time points and (B) multivariate analysis for overall survival among patients who had sequential cMRD assessment at two time points

References

    1. Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Queizán JA, Bárez A, et al. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers (Basel). 2023; 15: 1558. - PMC - PubMed
    1. Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019; 33: 1713-22. - PMC - PubMed
    1. Malhotra P, Yanamandra U, Khadwal A, Prakash G, Lad D, Law AD, et al. Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. Indian J Hematol Blood Transfus. 2018; 34: 261-7. - PMC - PubMed
    1. Asrar MM, Lad DP, Bansal D, Prinja S, Khadwal A, Prakash G, et al. Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. Leuk Lymphoma. 2021; 62: 3271-7. - PubMed
    1. Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, et al. Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India. Indian J Hematol Blood Transfus. 2017; 33: 31-40. - PMC - PubMed

LinkOut - more resources